2-(furan-2-yl)-3-methylquinoxaline

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: 2-(furan-2-yl)-3-methylquinoxaline
• 英文别名: 2-[2]furyl-3-methyl-quinoxaline；2-[2]Furyl-3-methyl-chinoxalin
• 化学式: C₁₃H₁₀N₂O
• 分子量: 210.235
• InChiKey: XSGSHZCWKJKGOS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  16
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.08
• 拓扑面积：
  38.9
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  alkaline earth salt of/the/ methylsulfuric acid 生成 2-(furan-2-yl)-3-methylquinoxaline
  参考文献：
  名称：

  Maurer et al., Chemische Berichte, 1935, vol. 68, p. 1716,1723

  摘要：

  DOI：

文献信息

• [EN] QUINOXALINYL DERIVATIVES<br/>[FR] DÉRIVÉS DE QUINOXALINYLE
  申请人：ENANTA PHARM INC

  公开号：WO2009073719A1

  公开（公告）日：2009-06-11

  The present invention relates to compounds of Formula (I) or (II), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising a compound of the present invention.

  本发明涉及以下结构的化合物（I）或（II），或其药用盐、酯或前药：它们抑制丝氨酸蛋白酶活性，特别是乙型肝炎病毒（HCV）NS3-NS4A蛋白酶的活性。因此，本发明的化合物干扰乙型肝炎病毒的生命周期，同时也可用作抗病毒药物。本发明还涉及包含上述化合物的药物组合物，用于治疗患有HCV感染的受试者。该发明还涉及通过给受试者施用本发明化合物的药物组合物来治疗HCV感染的方法。
• Chemoselective synthesis of quinoxalines and benzimidazoles by silica gel catalysis
  作者：Chunmei Li、Furen Zhang、Zhen Yang、Chenze Qi

  DOI：10.1016/j.tetlet.2014.08.022

  日期：2014.10

  Treatment of nitroolefins and o-phenylenediamine with silica gel catalyst produced quinoxalines mainly in THF, but gave benzimidazoles efficiently in water. Such a solvent-dependent chemoselective reaction has prominent features of affording two cyclized products selectively with the same substrate, short reaction time, operational simplicity, as well as available starting materials and nontoxic catalysts. In addition, the scope and limitations were explored and a plausible reaction mechanism is proposed. (C) 2014 Elsevier Ltd. All rights reserved.
• QUINOXALINYL DERIVATIVES
  申请人：Niu Deqiang

  公开号：US20090180981A1

  公开（公告）日：2009-07-16

  The present invention relates to compounds of Formula I or II, or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising a compound of the present invention.
• US8962551B2
  申请人：——

  公开号：US8962551B2

  公开（公告）日：2015-02-24
• Maurer et al., Chemische Berichte, 1935, vol. 68, p. 1716,1723
  作者：Maurer et al.

  DOI：——

  日期：——